GlassScriptPhysician profile
Alladdin Abosaida
NPI 1376777524
$1,928.96
in general payments reported to CMS, 2019-2025
29 companies · $702 in 2025
The $702 reported for 2025 was more than what 83% of Pediatric Pulmonology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $368 · 2022: $107 · 2023: $356 · 2024: $396 · 2025: $702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,453.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $382.43 | 2023-2025 | Fasenra, Tezspire |
| Ars Pharmaceuticals Operations, INC. | $171.07 | 2025 | Neffy |
| Chiesi USA, INC. | $165.32 | 2019-2023 | Bronchitol |
| Genentech USA, INC. | $139.98 | 2022-2025 | Xolair |
| Gilead Sciences, INC. | $125.00 | 2019 | |
| Galderma Laboratories, L.P. | $94.85 | 2025 | Nemluvio |
| Merck Sharp & Dohme LLC | $90.00 | 2019 | |
| Alcresta Therapeutics, INC. | $82.33 | 2022-2023 | Relizorb |
| Genzyme Corporation | $78.56 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $76.94 | 2023-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $76.33 | 2023-2025 | Takhzyro, Hyqvia |
| Amgen INC. | $69.38 | 2023-2025 | Tezspire |
| Glaxosmithkline, LLC. | $42.40 | 2019-2023 | Nucala |
| Abbvie INC. | $33.37 | 2022-2023 | Creon |
| Csl Behring | $32.11 | 2024 | Hizentra |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $28.10 | 2022-2024 | Alternaria Tenuis, Standardized Mite D. Farinae, Histamine Positive |
| Vertex Pharmaceuticals Incorporated | $27.14 | 2022-2023 | Trikafta |
| Optinose US, INC. | $25.44 | 2025 | |
| Nestle Healthcare Nutrition INC. | $20.22 | 2023 | |
| Pfizer INC. | $19.25 | 2024 | |
| Tactile Systems Technology INC | $19.14 | 2025 | Flexitouch Plus, Nimbl |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.79 | 2023 | Spiriva Respimat, Stiolto Respimat |
| Baxter Healthcare | $17.35 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Pharming Healthcare, INC. | $17.24 | 2023 | Ruconest |
| Grifols USA, LLC | $16.95 | 2025 | Xembify |
| Novartis Pharmaceuticals Corporation | $16.40 | 2024 | |
| Covis Pharma Gmbh | $16.32 | 2023 | |
| Phadia US INC. | $16.10 | 2023 | Immunocap |
| Allergan, INC. | $11.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alladdin Abosaida listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.